|
|
|
|
|
|
Sponsored by: |
Braintree Laboratories |
Information provided by: | Braintree Laboratories |
ClinicalTrials.gov Identifier: | NCT00164125 |
To evaluate the safety of extended use of polyethyleneglycol3350 laxative in constipated patients.
Condition | Intervention | Phase |
Constipation |
Drug: polyethyleneglycol3350 |
Phase IV |
MedlinePlus related topics: | Constipation |
Study Type: | Interventional |
Study Design: | Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment |
Official Title: | An Open Label Study of Chronic Polyethyleneglycol3350 Use in Constipated Patients |
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Inclusion Criteria:
Exclusion Criteria:
Patients currently taking any of the following medications that are known to effect bowel habits:
Show 47 Study Locations |
Braintree Laboratories |
Principal Investigator: | Jorge Herrera, MD | University of South Alabama |
Study ID Numbers: | 851-CR3 |
First Received: | September 9, 2005 |
Last Updated: | September 9, 2005 |
ClinicalTrials.gov Identifier: | NCT00164125 |
Health Authority: | United States: Food and Drug Administration |
|